Abstract
BC094916 overexpression suppressed Creb1 and Bcl2 transcription to induce cell apoptosis, which suppressed SP 2/0 proliferation and xenograft tumor progression. Thus, BC094916 overexpression may be a potential therapeutic agent for treatment of Multiple Myeloma (MM) and autoimmune diseases such as Systemic Lupus Erythematosus (SLE).
Introduction
Plasma cell-related diseases, including Multiple Myeloma (MM) and Systemic Lupus Erythematosus (SLE), are characterized by the uncontrolled survival and proliferation of plasma cells. While treatments exist for early-stage B cells, late-stage plasma cells often develop resistance to existing therapies. This study identifies BC094916 as a novel genetic regulator that is naturally silenced during the B-cell-to-plasma-cell transition. Researchers hypothesized that restoring its expression could act as a transcriptional "brake," forcing rogue plasma cells to undergo programmed cell death (apoptosis).
Methods
The study utilized the SP 2/0 mouse myeloma cell line as a model for human plasmablasts. Researchers engineered these cells using lentiviral vectors to overexpress BC094916.
Successful gene delivery was monitored via fluorescence microscopy and quantitative analysis. Functional assays included CCK8 for proliferation, FACS for apoptosis and cell cycle analysis, and a luciferase reporter system to investigate transcriptional repression of Creb1 and Bcl2 promoters. Finally, a xenograft mouse model was used to observe the effects on tumor progression in vivo over an eight-day period.
Results
Validation of Gene Overexpression
Quantitative analysis confirmed a significant increase in BC094916 mRNA levels in the transfected group compared to the empty vector control, validating the experimental model.
Tumor Suppression and Apoptosis
In the xenograft model, BC094916 overexpression led to a reduction in tumor volume by over 60% compared to controls (under 1.0 cm³ vs. 2.5 cm³). This suppression was driven by a near doubling of the apoptosis rate in myeloma cells.
Mechanism of Action: Transcriptional Repression
BC094916 acts as a transcriptional repressor in the nucleus. It binds to the promoters of two key survival genes:
- Bcl2: An anti-apoptotic protein. Its suppression removes the cell's primary shield against programmed death.
- Creb1: A transcription factor regulating eukaryotic translation factors (Eif/Eef). Its suppression shuts down protein synthesis necessary for growth.
Western blot analysis further confirmed that when BC094916 was active, levels of Bcl2 and Creb1 plummeted, while the pro-apoptotic protein p53 increased.
Discussion
The findings suggest that BC094916 acts as a critical regulator of plasma cell proliferation. Its absence in diseased states allows for unchecked growth. While the results in mouse models are compelling, translating this to human therapy involves challenges, such as confirming the function of the human ortholog IFI16 and developing safe, targeted gene delivery systems. Future research will focus on potential off-target effects and clinical applicability in MM and SLE patients.
Datasets are available in ArrayExpress under accessions E-MTAB-7105, 7106, 7109, 7110, and 7112.
Summary updated